Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.38 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.38 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.38 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MVD | P53602 | 1/20 | 0.33 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | PLA2G2C | Q5R387 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21764803 | 0.88 | CYP3A4 (0.50) | LPAR3LPAR1LPAR2ALDH1A1CYP3A4 | |
| SCHEMBL21764567 | 0.86 | LPAR3 (0.57) | LPAR3LPAR1LPAR2ALDH1A1CYP3A4 | |
| SCHEMBL27540332 | 0.86 | CYP3A4 (0.48) | LPAR3LPAR1LPAR2ALDH1A1CYP3A4 | |
| SCHEMBL1290380 | 0.82 | TSHR (0.42) | BTN3A1ALDH1A1LMNAHSD17B10 | |
| SCHEMBL28300641 | 0.82 | ALDH1A1 (0.50) | BTN3A1ALDH1A1KMT2ACYP3A4LMNA | |
| SCHEMBL27397877 | 0.81 | CYP3A4 (0.56) | LPAR3LPAR1LPAR2ALDH1A1CYP3A4 | |
| SCHEMBL497177 | 0.81 | LPAR3 (0.46) | LPAR3LPAR1LPAR2BTN3A1MEN1 | |
| SCHEMBL27951653 | 0.81 | CA4 (0.44) | LPAR3LPAR1LPAR2BTN3A1MEN1 | |
| SCHEMBL2638491 | 0.80 | TSHR (0.42) | LPAR3LPAR1LPAR2BTN3A1ALDH1A1 | |
| SCHEMBL27304148 | 0.80 | ALDH1A1 (0.48) | BTN3A1ALDH1A1KMT2ACYP3A4LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | AEQUOR, INC. (US) | 2023-11-23 | — | — | US | disclosed |
| CN-105530823-B | Food composition | 株式会社大塚制药工场 | 2021-03-23 | — | — | CN | disclosed |
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | AEQUOR, INC. | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200060280-A1 | Antimicrobial Compounds and Methods of Use | DDT, PFAS, DSTN | LPAR3 3397/4885LPAR1 3108/4885LPAR2 3576/4885 |
| US-20230371517-A1 | COMBINATIONS TREATMENTS | DDT, AS3MT, GPX4 | LPAR3 1324/4885LPAR1 1238/4885LPAR2 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.